ARCHIVES

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Bypass Budget Omits Needless Words: Faster Progress to Cost $421 Million More

March 29, 1996

Mantel Film Getting Rave Reviews, Not Enough Air Time

July 18, 1986

NCI-Approved Clinical Trials Listed For June 2001

July 27, 2001

Oncology Nurses Urged To Help Set Agenda For Health Care Reform

May 29, 1992

Cancer Meetings Listed

April 18, 1997

DCPC Board Approves Concepts Of Six New RFAs Totaling $9.3 Million A Year

May 11, 1984